Aytu BioPharma (AYTU) Competitors $1.34 -0.02 (-1.11%) Closing price 05/1/2025 03:57 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 05/1/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. GDTC, CLNN, BCAB, CGTX, DARE, CVM, GRCE, CASI, EGRX, and OVIDShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include CytoMed Therapeutics (GDTC), Clene (CLNN), BioAtla (BCAB), Cognition Therapeutics (CGTX), Daré Bioscience (DARE), CEL-SCI (CVM), Grace Therapeutics (GRCE), CASI Pharmaceuticals (CASI), Eagle Pharmaceuticals (EGRX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. CytoMed Therapeutics Clene BioAtla Cognition Therapeutics Daré Bioscience CEL-SCI Grace Therapeutics CASI Pharmaceuticals Eagle Pharmaceuticals Ovid Therapeutics Aytu BioPharma (NASDAQ:AYTU) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk. Which has better valuation & earnings, AYTU or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than Aytu BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAytu BioPharma$77.23M0.11-$15.84M-$1.45-0.92CytoMed TherapeuticsN/AN/A-$3.13MN/AN/A Does the MarketBeat Community prefer AYTU or GDTC? Aytu BioPharma received 251 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 67.11% of users gave Aytu BioPharma an outperform vote. CompanyUnderperformOutperformAytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Which has more risk & volatility, AYTU or GDTC? Aytu BioPharma has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Do analysts rate AYTU or GDTC? CytoMed Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 112.31%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytoMed Therapeutics is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of AYTU or GDTC? 33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 3.6% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is AYTU or GDTC more profitable? CytoMed Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -7.62%. CytoMed Therapeutics' return on equity of 0.00% beat Aytu BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Aytu BioPharma-7.62% -19.30% -4.80% CytoMed Therapeutics N/A N/A N/A Does the media refer more to AYTU or GDTC? In the previous week, CytoMed Therapeutics had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for CytoMed Therapeutics and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.87 beat CytoMed Therapeutics' score of 1.37 indicating that Aytu BioPharma is being referred to more favorably in the media. Company Overall Sentiment Aytu BioPharma Very Positive CytoMed Therapeutics Positive SummaryCytoMed Therapeutics beats Aytu BioPharma on 9 of the 15 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.24M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.927.3222.5918.54Price / Sales0.11241.43401.35103.29Price / CashN/A65.8538.1834.62Price / Book0.296.486.774.25Net Income-$15.84M$143.41M$3.22B$248.18M7 Day Performance21.92%2.58%1.39%1.03%1 Month Performance16.09%5.00%2.78%2.70%1 Year Performance-55.65%-3.72%15.85%4.05% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma1.6884 of 5 stars$1.34-1.1%N/A-53.9%$8.24M$77.23M-0.92160High Trading VolumeGDTCCytoMed Therapeutics2.1501 of 5 stars$2.41+5.7%$5.00+107.5%+10.0%$26.37MN/A0.00N/AGap DownCLNNClene2.836 of 5 stars$3.03+1.0%$50.20+1,556.8%-65.7%$26.05M$342,000.00-0.57100Upcoming EarningsBCABBioAtla2.8785 of 5 stars$0.44+1.0%$6.00+1,248.6%-85.2%$25.98M$11M-0.2660Upcoming EarningsNews CoverageCGTXCognition Therapeutics3.6325 of 5 stars$0.42-4.9%$7.13+1,610.7%-77.1%$25.81MN/A-0.4320Upcoming EarningsShort Interest ↓News CoverageDAREDaré Bioscience2.281 of 5 stars$2.89-3.0%$24.00+730.4%-26.0%$25.58M$9,784.00-4.8930Short Interest ↓Positive NewsCVMCEL-SCIN/A$0.30+4.6%N/A-81.3%$25.57MN/A-0.6343Analyst ForecastNews CoverageGRCEGrace Therapeutics2.3855 of 5 stars$2.51+0.8%$12.00+378.1%N/A$25.45MN/A-2.16N/APositive NewsGap DownCASICASI Pharmaceuticals3.8438 of 5 stars$2.03-1.0%$4.00+97.0%-14.9%$24.97M$28.54M-0.91180EGRXEagle PharmaceuticalsN/A$1.92+12.9%N/A-53.2%$24.94M$257.55M0.00100Analyst ForecastGap DownOVIDOvid Therapeutics4.4513 of 5 stars$0.35+0.9%$3.03+766.7%-89.7%$24.88M$566,000.00-0.7460Gap Up Related Companies and Tools Related Companies CytoMed Therapeutics Alternatives Clene Alternatives BioAtla Alternatives Cognition Therapeutics Alternatives Daré Bioscience Alternatives CEL-SCI Alternatives Grace Therapeutics Alternatives CASI Pharmaceuticals Alternatives Eagle Pharmaceuticals Alternatives Ovid Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AYTU Stock Free AYTU Stock Alerts